Product Details
Place of Origin: China
Brand Name: Quickoolchem
Payment & Shipping Terms
Minimum Order Quantity: 50 grams
Price: Negotiable
Packaging Details: 1kg/Bag; 25kg/Carton
Delivery Time: 2-3 days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 10 MT/Month
Synonyms: |
EIDD-2801; MK-4482; Molnupiravir Prodrug |
Density: |
1.46 G/cm3 |
Purity: |
≥99% |
Solubility: |
Soluble In DMSO And Methanol |
Refractive Index: |
1.617 |
Molecular Formula: |
C13H19N3O7 |
Boiling Point: |
~600.3°C At 760 MmHg |
Flash Point: |
316.5°C |
Package: |
1kg/bag, 25kg/drum |
Origin: |
China |
Synonyms: |
EIDD-2801; MK-4482; Molnupiravir Prodrug |
Density: |
1.46 G/cm3 |
Purity: |
≥99% |
Solubility: |
Soluble In DMSO And Methanol |
Refractive Index: |
1.617 |
Molecular Formula: |
C13H19N3O7 |
Boiling Point: |
~600.3°C At 760 MmHg |
Flash Point: |
316.5°C |
Package: |
1kg/bag, 25kg/drum |
Origin: |
China |
FIP is a complex and challenging disease caused by certain strains of feline coronavirus (FCoV). It can manifest in various forms, including wet (effusive) and dry (non-effusive) forms, and it often progresses rapidly, leading to severe illness and death in affected cats.
Molnupiravir has shown promising antiviral activity against a broad spectrum of RNA viruses, including coronaviruses. In theory, it could potentially inhibit the replication of the FCoV responsible for FIP. However, translating this theoretical potential into practical treatment requires rigorous clinical evaluation.
If considering Molnupiravir or any other experimental treatment for FIP, it's crucial to work closely with a veterinarian experienced in managing the disease. They can provide guidance on treatment options, potential risks, and help design a comprehensive care plan tailored to the individual cat's needs.
| Parameter | Value |
|---|---|
| Boiling Point | ~600.3°C At 760 MmHg |
| Cas Number | 2349386-89-4 |
| Synonyms | EIDD-2801; MK-4482; Molnupiravir Prodrug |
| Flash Point | 316.5°C |
| Solubility | Soluble In DMSO And Methanol |
| Refractive Index | 1.617 |
| Storage | Store At -20°C |
| Purity | ≥99% |
| Appearance | White To Off-white Powder |
COVID-19 Treatment: One of the most significant applications of molnupiravir is in the treatment of COVID-19. Clinical trials have indicated that it can reduce the duration of symptoms and decrease the risk of hospitalization in patients with mild to moderate COVID-19. If approved by regulatory agencies, it could become an essential tool in managing the pandemic.
Antiviral Therapy: Molnupiravir's mechanism of action involves inducing errors in the genetic material of the virus, inhibiting its replication. This broad-spectrum antiviral activity suggests potential applications beyond COVID-19, including other viral infections such as influenza and respiratory syncytial virus (RSV).
Preventive Treatment: There is ongoing research into the use of molnupiravir as a preventive measure against viral infections. If proven effective, it could be used prophylactically in high-risk populations or during outbreaks to limit the spread of viral diseases.
Animal Health: Molnupiravir might also find applications in veterinary medicine for treating viral infections in animals. This could be particularly relevant for diseases that affect livestock or companion animals.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
